Previous 10 | Next 10 |
2023-05-02 15:43:45 ET The U.S. Food and Drug Administration (FDA) on Tuesday issued a draft guidance to offer further support for decentralized clinical trials (DCTs) where studies for treatments and medical devices can take place beyond traditional trial sites. DCTs can lower the barr...
The U.S. market for medicines grew by 5% in 2022, reaching a total value of $429Bn Health services utilization reached 100% of pre-pandemic levels for the first time at the end of 2022, up from a low of 66% in Q2 of 2020 Telehealth visits fell to 5% of total visits in 2022, down f...
2023-04-27 14:33:00 ET IQVIA Holdings ( NYSE: IQV ) and ICON Public Limited ( NASDAQ: ICLR ) led decliners in the contract research space Thursday after the companies reiterated the guidance despite reporting better-than-expected Q1 2023 financials. IQV shares have reach...
2023-04-27 12:25:11 ET IQVIA Holdings Inc. (IQV) Q1 2023 Earnings Conference Call April 27, 2023, 09:00 AM ET Company Participants Nick Childs - Senior Vice President, Investor Relations and Treasurer Ari Bousbib - Chairman and Chief Executive Officer Ron Bruehlm...
2023-04-27 07:10:21 ET IQVIA press release ( NYSE: IQV ): Q1 Non-GAAP EPS of $2.45 beats by $0.04 . Revenue of $3.65B (+2.2% Y/Y) beats by $40M . Shares -1.31% PM. Reaffirms full-year 2023 guidance For further details see: IQVIA Non-GAAP E...
Revenue of $3,652 million GAAP Net Income of $289 million, Adjusted EBITDA of $851 million GAAP Diluted Earnings per Share of $1.53, Adjusted Diluted Earnings per Share of $2.45 R&D Solutions quarterly bookings of $2.6 billion, representing book-to-bill ratio of 1.28x ...
2023-04-26 12:13:10 ET IQVIA ( NYSE: IQV ) is scheduled to announce Q1 earnings results on Thursday, April 27th, before market open. The consensus EPS Estimate is $2.41 (-2.4% Y/Y) and the consensus Revenue Estimate is $3.61B (+1.1% Y/Y). Over the last 2 years, IQV h...
IQVIA™ (NYSE:IQV), a leading global provider of advanced analytics, technology solutions and clinical research services to the pharmaceutical and broader life sciences industry, today announces the company has been recognized as a Leader in Customer Experience Platforms (CXP) by Everest Gr...
2023-04-12 17:19:34 ET Summary Dealreporter article says that multiple PE firms are bidding for the company and even named advisors the company has hired. Private equity math works given relatively low current leverage and high cash generation. Even though the stock is decentl...
2023-04-12 02:26:28 ET Summary The White House's announcement on drug price caps caused a significant drop in biopharma stocks during Q1 2023. The impact of drug pricing-related caps and pressure will likely be limited, and the industry is expected to adapt and find new revenue st...
News, Short Squeeze, Breakout and More Instantly...
2024-07-23 10:00:13 ET Jailendra Singh from Truist Financial issued a price target of $300.00 for IQV on 2024-07-23 09:26:00. The adjusted price target was set to $300.00. At the time of the announcement, IQV was trading at $240.265. The overall price target consensus is...
2024-07-23 10:00:11 ET Elizabeth Anderson from Evercore ISI issued a price target of $270.00 for IQV on 2024-07-23 08:59:00. The adjusted price target was set to $270.00. At the time of the announcement, IQV was trading at $239.5. The overall price target consensus is at...
2024-07-23 07:00:06 ET Luke Sergott from Barclays issued a price target of $275.00 for IQV on 2024-07-23 05:25:00. The adjusted price target was set to $275.00. At the time of the announcement, IQV was trading at $245.23. The overall price target consensus is at $273.93 ...